Holen Sie sich die Stockscreener-App
0.7501
3.32%
0.0241
Handel nachbörslich:
.75
-0.000100
-0.01%
Decoy Therapeutics Inc Aktie (DCOY) Neueste Nachrichten
Decoy Therapeutics Joins Webull Corporate Connect Service Platfo - GuruFocus
Decoy Therapeutics Joins Webull Corporate Connect Service Platform - marketscreener.com
Follow Decoy Therapeutics updates on Webull app now - Stock Titan
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial - Finviz
Decoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment Agreement - Finviz
Gates Foundation backs Decoy's push for rapid, low-cost antivirals - Stock Titan
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | DCOY Stock News - Longbridge
This MasTec Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Decoy Therapeutics (DCOY) Receives "Buy" Rating from Ladenburg T - GuruFocus
Hanish, director at Salarius, sells shares worth $17 By Investing.com - Investing.com Nigeria
DCOY Stock Price, News & Analysis - Stock Titan
DCOY Stock Price and Chart — NASDAQ:DCOY - TradingView — Track All Markets
Decoy Therapeutics Inc. (DCOY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - marketscreener.com
Decoy Therapeutics Reaches Global Access Commitment Agreement With Gates Foundation; Stock Up - Nasdaq
Decoy Therapeutics Faces Challenges Amid Market Fluctuations - StocksToTrade
Decoy Therapeutics Faces Major Headwinds Amid Financial Struggles - timothysykes.com
Decoy Therapeutics reaches global access commitment agreement to focus on development of a globally accessible, scalable peptide-conjugate manufacturing platform - marketscreener.com
Decoy Therapeutics rises as Gates Foundation backs antiviral drug access - TradingView
Decoy Therapeutics Reaches Global Access Commitment Agreement To Focus On Development Of A Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - TradingView — Track All Markets
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PR Newswire
Salarius Pharmaceuticals shareholders re-elect directors and approve proposals at annual meeting - Investing.com Nigeria
Salarius announces planned corporate name change to Decoy Therapeutics - MSN
Salarius Pharmaceuticals Rebrands as Decoy Therapeutics on Nasdaq - The Globe and Mail
DCOY - Finviz
Salarius Pharmaceuticals changes name to Decoy Therapeutics - marketscreener.com
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker By Investing.com - Investing.com Australia
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics By Investing.com - Investing.com South Africa
Salarius Pharmaceuticals to rebrand as Decoy Therapeutics, change ticker - Investing.com
Salarius Pharmaceuticals stock soars on name change to Decoy Therapeutics - Investing.com
Salarius Pharmaceuticals, Inc. Announces Rebranding to Decoy Therapeutics Inc. with Nasdaq Trading Under DCOY Starting January 8, 2026 - Quiver Quantitative
Salarius Pharmaceuticals Changes Corporate Name to Decoy - GlobeNewswire
Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics - The Manila Times
Hanish, director at Salarius, sells shares worth $17 - Investing.com
Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - GlobeNewswire
Salarius to change name to Decoy Therapeutics, adopt DCOY ticker - Investing.com
Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - The Manila Times
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - GlobeNewswire
Salarius Pharmaceuticals clarifies continued Nasdaq listing after merger - Investing.com
Salarius Pharmaceuticals and Decoy Therapeutics Finalize Merger - citybiz
Salarius Pharmaceuticals Explorates Merger and Funding Moves - StocksToTrade
Salarius Pharmaceuticals, Inc. (SLRX) Stock: Plunges 51% After $7M Public Offering Announcement - parameter.io
Salarius Pharma Stock Jumps After-Hours As Nasdaq Compliance Clears Path For Decoy Merger — Retail Bulls Bet On Breakout - Stocktwits
Salarius Pharmaceuticals amends merger terms, adjusts preferred stock conversion - Investing.com
Salarius Pharmaceuticals Regains Nasdaq Compliance with Minimum Bid Price Requirement - Quiver Quantitative
Salarius Pharmaceuticals appoints Mark J. Rosenblum as acting CEO - Investing.com
Salarius Pharmaceuticals Appoints New Acting CEO - TipRanks
Salarius Pharmaceuticals to implement 1-for-15 reverse stock split - Investing.com
Decoding Salarius Pharmaceuticals’ Stock Movement - timothysykes.com
Salarius Pharmaceuticals granted Nasdaq extension to regain listing compliance - Investing.com
Salarius Pharmaceuticals amends merger agreement to allow debt-for-equity exchange - Investing.com
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard - Yahoo Finance
Salarius Pharmaceuticals shareholders approve reverse stock split and share issuance - Investing.com
Salarius Pharmaceuticals adjusts merger terms amid market shifts - Investing.com
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):